about
Economic evaluations of implantable cardioverter defibrillators: a systematic review.Intracameral cefuroxime and moxifloxacin used as endophthalmitis prophylaxis after cataract surgery: systematic review of effectiveness and cost-effectiveness.Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in EuropePatient participation in a Clinical Guideline Development for Systemic Lupus Erythematosus.METHODOLOGICAL QUALITY OF ECONOMIC EVALUATIONS ALONGSIDE TRIALS OF KNEE PHYSIOTHERAPY.Social/economic costs and quality of life in patients with haemophilia in Europe.On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe.Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe.Social/economic costs and health-related quality of life in patients with histiocytosis in Europe.Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe.Social/economic costs and health-related quality of life in patients with scleroderma in Europe.Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe.Validation of the Spanish version of the Oxford knee score and assessment of its utility to characterize quality of life of patients suffering from knee osteoarthritis: a multicentric study.Social economic costs and health-related quality of life in patients with systemic sclerosis in Spain.Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review.Cost-of-Illness in Rare Diseases.Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe.Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe.Social/economic costs and health-related quality of life in patients with rare diseases in Europe.[Management of benign melanocytic lesions as a melanoma prevention. Systematic review].Cost-effectiveness of vaccines for the prevention of seasonal influenza in different age groups: a systematic reviewCost-effectiveness of Platelet-Rich Plasma for Diabetic Foot Ulcer in SpainEarly Detection, Diagnosis and Intervention Services for Young Children with Autism Spectrum Disorder in the European Union (ASDEU): Family and Professional Perspectives
P50
Q33164873-481BB78F-CF59-4CDE-B540-935895E7119CQ34073735-CE48A079-3C73-43D9-8E8B-31DA1FCE26C8Q36908255-47A97E45-6294-46BB-9186-D8198C3F1209Q38533497-50342187-0E7F-4EC0-9067-F19E54292EE0Q38635205-E17C316C-E813-4E60-A5B9-FED881B60CB6Q38885402-102CE8AE-922B-4E42-AE5B-29A8C3756C47Q38938018-C4C9FDB3-490C-4F2C-8574-FD08B3B84A62Q39845094-CAABECD9-4883-4A27-97F0-AFDD9A96E819Q39855919-98FC119C-645A-4BC6-AA44-7BE48D82CD4CQ39865697-F0436299-BA0D-41AD-91D2-C4355CDEFB3DQ39869184-F5393392-5C16-473C-984C-51FE00E00D2DQ39869191-878010BE-453A-46CA-8212-8FF781445EF8Q39869199-3BD55229-F13E-499C-AB4C-1EDDEA0CFFCFQ42050956-E4231519-3401-49BD-AB43-A468860C3339Q44445656-330DA732-0561-4F16-9718-33259271305FQ47296123-7ECBD407-1E9A-4578-9E40-38348626D150Q47353417-FBDA3A09-2181-407C-8896-E067ECD64F07Q47777225-8BDFA3A2-FDBD-4521-B59F-078B9D380C99Q47777858-7506CDCE-44D8-4A84-BA47-B5605024F1BCQ47787703-118B8529-E1CC-4ABB-B8FA-352904622D0BQ50246626-74EFACE4-6CCB-4961-B382-64F4AE2CB84BQ57454992-C47DD928-6CF9-4191-9601-AA987499EC47Q89618688-11571CFF-D259-4897-9264-9A8B3B809379Q90674107-5252474D-E34E-4025-8A8E-142868AD74CB
P50
description
researcher ORCID ID = 0000-0002-0138-9252
@en
wetenschapper
@nl
name
Renata Linertová
@ast
Renata Linertová
@en
Renata Linertová
@es
Renata Linertová
@nl
type
label
Renata Linertová
@ast
Renata Linertová
@en
Renata Linertová
@es
Renata Linertová
@nl
prefLabel
Renata Linertová
@ast
Renata Linertová
@en
Renata Linertová
@es
Renata Linertová
@nl
P106
P21
P31
P496
0000-0002-0138-9252